Aktienanalyse zu Teleflex Inc (TFX)TFXTeleflex Inc

Teleflex Incorporated is a global provider of medical technologies. The Company offers a diverse portfolio with solutions in the therapy areas of anesthesia, emergency medicine, interventional cardiology and radiology, surgical, and vascular access. It primarily designs, develops, manufactures and supplies single-use medical devices used by hospitals and healthcare providers for common diagnostic and therapeutic procedures in critical care and surgical applications. It operates in three segments: the Americas, EMEA (Europe, the Middle East and Africa) and Asia (Asia Pacific). Its vascular access product portfolio includes Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous (bone access) systems. Its interventional product offerings consist of a portfolio of the MANTA Vascular Closure device, Arrow OnControl powered bone biopsy system, GuideLiner, Turnpike and TrapLiner catheters. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Teleflex Inc is a good buy right now due to its recent FDA approval for the EZPLAZ freeze-dried plasma, which enhances its market position in emergency medicine. Additionally, the forward P/E ratio of 11.01 indicates potential for growth compared to its current price of $125.12. The RSI of 50.30 suggests the stock is neither overbought nor oversold, providing a balanced entry point.

12 analysts cover TFX: 10 rate it Buy, 2 Hold and 0 Sell. The average price target is 136.20.